<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001049.pub5" GROUP_ID="INJ" ID="420799072011522466" MERGED_FROM="" MODIFIED="2013-08-06 09:51:21 +0100" MODIFIED_BY="Emma Sydenham" REVIEW_NO="INJ0103" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2013-08-06 09:50:46 +0100" MODIFIED_BY="Emma Sydenham">
<TITLE>Mannitol for acute traumatic brain injury</TITLE>
<CONTACT>
<PERSON ID="19252" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Abel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wakai</LAST_NAME>
<SUFFIX>MD FRCSI FCEM</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>awakai@rcsi.ie</EMAIL_1>
<EMAIL_2>abelwakai@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Emergency Care Research Unit (ECRU)</DEPARTMENT>
<ORGANISATION>Division of Population Health Sciences (PHS), Royal College of Surgeons in Ireland</ORGANISATION>
<ADDRESS_1>123 St. Stephen's Green</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dublin 2</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<PHONE_1>+353 1 402 2304/06</PHONE_1>
<PHONE_2/>
<FAX_1>+353 1 402 2764</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-08-06 09:50:14 +0100" MODIFIED_BY="Emma Sydenham">
<PERSON ID="19252" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Abel</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wakai</LAST_NAME>
<SUFFIX>MD FRCSI FCEM</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>awakai@rcsi.ie</EMAIL_1>
<EMAIL_2>abelwakai@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Emergency Care Research Unit (ECRU)</DEPARTMENT>
<ORGANISATION>Division of Population Health Sciences (PHS), Royal College of Surgeons in Ireland</ORGANISATION>
<ADDRESS_1>123 St. Stephen's Green</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dublin 2</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<PHONE_1>+353 1 402 2304/06</PHONE_1>
<PHONE_2/>
<FAX_1>+353 1 402 2764</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="43642135541594015653100422154204" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Aileen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McCabe</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>aileenmccabe@rcsi.ie</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Emergency Care Research Unit (ECRU)</DEPARTMENT>
<ORGANISATION>Division of Population Health Sciences (PHS), Royal College of Surgeons in Ireland</ORGANISATION>
<ADDRESS_1>123 St. Stephen's Green</ADDRESS_1>
<ADDRESS_2/>
<CITY>Dublin 2</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<PHONE_1>00 353 1 402 2304</PHONE_1>
<PHONE_2/>
<FAX_1>00 353 1 402 2764</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8053" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Epidemiology &amp; Public Health</POSITION>
<EMAIL_1>Ian.Roberts@Lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL>http://injuries.cochrane.org</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Injuries Group</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>North Courtyard</ADDRESS_1>
<ADDRESS_2>Keppel Street</ADDRESS_2>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7958 8128</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7299 4663</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14465" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Gillian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schierhout</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>gillsch@optusnet.com.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>c/o Cochrane Injuries Group</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>Keppel Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-08-06 09:50:14 +0100" MODIFIED_BY="Emma Sydenham">
<UP_TO_DATE>
<DATE DAY="20" MONTH="4" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="4" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-06 09:50:46 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-08-06 09:50:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Copy edits made to the text.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-08-06 09:50:33 +0100" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-06 09:50:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>The search has been updated to April 2009. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-06 09:50:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>The search has been updated to April 2009. No new trials were identified. The conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-05-05 15:37:22 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="10" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-07-10 15:30:55 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="22" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>November 2006<BR/>In response to concerns raised about the integrity of the data from the trials by Cruz et al, the Cochrane Injuries Group undertook an investigation in which attempts were made to find out where the patients were recruited and to access the original trial data for external validation. Despite considerable efforts the Group is unable to provide any reassurance about the integrity of trial data and for this reason the trials in question have been removed from the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Emergency Medicine, St. Vincent's University Hospital, Dublin 4</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS R&amp; D Programme: mother and child health</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Higher Specialist Training Scheme in Emergency Medicine</NAME>
<COUNTRY CODE="IE">Ireland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-28 17:35:46 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-08-07 10:56:41 +0100" MODIFIED_BY="Emma M Sydenham">
<TITLE MODIFIED="2008-07-10 15:31:53 +0100" MODIFIED_BY="Emma M Sydenham">Mannitol for acute traumatic brain injury</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-07 10:56:41 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Mannitol is a sugar alcohol solution which is sometimes effective in reducing brain swelling after head injury. However, its effectiveness in the ongoing treatment of severe head injury remains unclear. There is evidence that excessive administration of mannitol may be harmful, by mannitol passing from the bloodstream into the brain, where it increases pressure within the skull and worsens brain swelling. The review authors searched the medical literature and identified four randomized controlled trials comparing mannitol to other treatment strategies for reducing brain swelling after head injury. One trial compared treatment with mannitol directed by measurement of the pressure within the skull (intracranial pressure) with &#8216;standard treatment&#8217; (treatment without measurement of intracranial pressure). One trial compared treatment with mannitol to treatment with pentobarbital (a barbiturate drug). One trial compared treatment with mannitol to treatment with hypertonic saline (highly concentrated salt solution). One trial compared treatment with mannitol to treatment with placebo (an inactive &#8216;dummy&#8217; solution) before arrival in the hospital (pre-hospital). The review found that treatment with mannitol for increased intracranial pressure reduced the likelihood of death when compared to treatment with pentobarbital. In contrast, it found that treatment with mannitol may increase the likelihood of death when compared to treatment with hypertonic saline. The review also found a small benefit when mannitol treatment is directed by measurement of intracranial pressure compared to &#8216;standard treatment.&#8217; The review found insufficient data on the effectiveness of pre-hospital administration of mannitol.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-05-28 16:16:54 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Mannitol is sometimes effective in reversing acute brain swelling, but its effectiveness in the ongoing management of severe head injury remains unclear. There is evidence that, in prolonged dosage, mannitol may pass from the blood into the brain, where it might cause increased intracranial pressure.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of different mannitol therapy regimens, of mannitol compared to other intracranial pressure (ICP) lowering agents, and to quantify the effectiveness of mannitol administration given at other stages following acute traumatic brain injury.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-05-28 16:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Injuries Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE (OvidSP), EMBASE (OvidSP), ISI Web of Science (SCI-EXPANDED &amp; CPCI-S) and PubMed. We checked reference lists of trials and review articles, and contacted authors of trials. The search was updated on the 20th April 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of mannitol, in patients with acute traumatic brain injury of any severity. The comparison group could be placebo-controlled, no drug, different dose, or different drug. We excluded cross-over trials, and trials where the intervention was started more than eight weeks after injury. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently rated quality of allocation concealment and extracted the data. Relative risks (RR) and 95% confidence intervals (CI) were calculated for each trial on an intention to treat basis. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We identified four eligible randomised controlled trials. One trial compared ICP-directed therapy to 'standard care' (RR for death = 0.83; 95% CI 0.47 to 1.46). One trial compared mannitol to pentobarbital (RR for death = 0.85; 95% CI 0.52 to 1.38). One trial compared mannitol to hypertonic saline (RR for death = 1.25; 95% CI 0.47 to 3.33). One trial tested the effectiveness of pre-hospital administration of mannitol against placebo (RR for death = 1.75; 95% CI 0.48 to 6.38).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Mannitol therapy for raised ICP may have a beneficial effect on mortality when compared to pentobarbital treatment, but may have a detrimental effect on mortality when compared to hypertonic saline. ICP-directed treatment shows a small beneficial effect compared to treatment directed by neurological signs and physiological indicators. There are insufficient data on the effectiveness of pre-hospital administration of mannitol. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-05-28 17:35:46 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Mannitol is widely used in the control of raised intracranial pressure following brain injury. A 1995 survey of the critical care management of head-injured patients in the United States showed that 83% of centres used osmotic diuretics in more than half of severely head-injured patients (<LINK REF="REF-Ghajar-1995" TYPE="REFERENCE">Ghajar 1995</LINK>). A survey in the United Kingdom showed that 100% of neurosurgical centres used mannitol in the treatment of raised intracranial pressure (<LINK REF="REF-Jeevaratnam-1996" TYPE="REFERENCE">Jeevaratnam 1996</LINK>; <LINK REF="REF-Matta-1996" TYPE="REFERENCE">Matta 1996</LINK>). The effectiveness of mannitol for head-injured patients in a critical condition is considered to be well established, without the need for randomised controlled trials. </P>
<P>For other patients, the Brain Trauma Foundation Guidelines Task Force of the American Association of Neurological Surgeons and Joint Section in Neurotrauma and Critical Care (<LINK REF="REF-Task-Force-1995" TYPE="REFERENCE">Task Force 1995</LINK>) recommend that mannitol be used only if the patient has signs of raised intracranial pressure (ICP) or deteriorating neurological status. In these circumstances, any adverse effects are most likely to be outweighed by therapeutic benefit. Nevertheless, the guidelines acknowledge that this is an area of considerable clinical uncertainty. There is uncertainty over the optimal treatment regimen, over the effectiveness of mannitol as compared to other ICP-lowering agents and over the usefulness of mannitol given at other stages following head injury, for example in the pre-hospital setting, prior to volume resuscitation.</P>
<P>We conducted a systematic review of randomised controlled trials that compared different mannitol treatment regimens, or compared mannitol to alternative interventions or placebo, at any stage in the acute management of head injury.</P>
</BACKGROUND>
<OBJECTIVES>
<P>1. To compare the effectiveness of mannitol therapy when given in different doses and for different durations.<BR/>2. To quantify the effectiveness of mannitol compared to other ICP-lowering agents.<BR/>3. To quantify the effectiveness of mannitol administration given at other stages following head injury.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-05-28 16:14:45 +0100" MODIFIED_BY="Emma M Sydenham">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Controlled trials in which subjects were assigned to treatment or control groups (placebo-controlled, no drug, different drug or different mannitol regimen) on the basis of random or quasi-random allocation. We excluded trials with a cross-over design.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants had a clinically defined acute traumatic brain injury of any severity.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The treatment group received mannitol in any dose for any duration, at any time within eight weeks following injury. The control group received any of the following: mannitol in a different dose from the treatment group, another ICP-lowering agent such as barbiturates or placebo or standard care only.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>We aimed to extract from each trial the number of patients originally allocated to each group. Within each group, we aimed to extract the number of participants who died from any cause during the follow-up period or who were dead, in a vegetative state or severely disabled, compared to moderate or good recovery (according to Glasgow Coma Scale [GCS] criteria).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-05-28 16:14:45 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The search was limited by date, language or publication type.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-05-28 16:14:45 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The Cochrane Injuries Group Trials Search Co-ordinator searched the following:</P>
<OL>
<LI>Cochrane Injuries Group Specialised Register (20th April 2009);</LI>
<LI>CENTRAL (<I>The Cochrane Library</I> 2009, Issue 2);</LI>
<LI>MEDLINE (OvidSP) (1950 to April 2009);</LI>
<LI>EMBASE (OvidSP) (1980 to April 2009);</LI>
<LI>ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 1970 to April 2009;</LI>
<LI>Conference Proceedings Citation Index- Science (CPCI-S) 1990 to April 2009;</LI>
<LI>PubMed (added in last 6 months; searched 21 April 2009).</LI>
</OL>
<P>Search strategies are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-08 15:02:44 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The reference lists of all relevant articles identified were checked. A letter was sent to the first author of reports to ask for further information on the published report and asking them to assist in identifying any further trials which may have been conducted by them, or other investigators. Eligibility was determined by reading the reports of possible trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>We determined eligibility by reading the reports of possible trials and corresponding with the trialists. The reviewers independently rated quality of allocation concealment and independently extracted the data. We resolved disagreement by discussion. We calculated relative risks and 95% confidence intervals for each trial on an intention to treat basis. For trials which used comparable treatment regimens, we planned to calculate summary relative risks and 95% confidence intervals using a fixed effects model, and to stratify the analyses on allocation concealment.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-05-28 17:35:46 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-05-11 14:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies met the inclusion criteria.</P>
<P>
<LINK REF="STD-Sayre-1996" TYPE="STUDY">Sayre 1996</LINK> compared the pre-hospital administration of mannitol with placebo (normal saline). Eligible patients were those with moderate and severe head injury (GCS 11 or less), above 18 years of age. Patients were excluded if they may have been pregnant, had already received a diuretic, or were receiving cardiopulmonary resuscitation. The mannitol group received 5ml/kg of 20% mannitol through a large bore IV catheter over five minutes. The placebo group was given 5ml/kg of 0.9% saline solution. Forty-four participants were randomised; three were later excluded as they were found to be ineligible. The treatment to which these three patients were allocated, as well as follow-up information were unavailable. Therefore, the analysis was based upon 20 participants in the mannitol group and 21 participants in the placebo group. Length of follow-up was for two hours after arrival at the hospital.</P>
<P>
<LINK REF="STD-Schwartz-1984" TYPE="STUDY">Schwartz 1984</LINK> compared mannitol to pentobarbital. Patients with severe head injury (GCS &lt;8), and with raised ICP for longer than 15 minutes were eligible. Treatment allocation was stratified according to the presence of intracranial haematomas. The mannitol group received 20% mannitol solution at an initial dose of 1g per kg. Additional increments were given to maintain the intracranial pressure at less than 20 torr, within a serum osmolality of mannitol of 320mOs/litre. The pentobarbital group received pentobarbital as an intravenous (IV) bolus of up to 10mg/kg, followed by a continuous infusion at 0.5 to 3mg/kg/hr, provided that CPP remained above 50 torr. Additional increments of pentobarbital were given to maintain the intracranial pressure at less than 20 torr. For subsequent episodes of raised ICP, there was some cross-over to the alternate treatment group, but the analysis was on the original intent-to-treat. Seventy participants were randomised; 11 were later deemed ineligible and excluded. Data on the treatment to which these 11 patients were allocated and follow-up information were unavailable. Therefore, the analysis was based on 31 participants in the mannitol group and 28 participants in the pentobarbital group. Length of follow-up was one year.</P>
<P>
<LINK REF="STD-Smith-1986" TYPE="STUDY">Smith 1986</LINK> compared two regimens for guiding the administration of mannitol, one according to neurological signs and physiological measurements, and the other using ICP monitoring. Participants had a severe head injury (GCS 8 or less). The protocol for the first group used neurological signs, GCS, ventilatory values and arterial blood gas to guide administration of mannitol. In the second group, a 250ml bolus of mannitol (20%) was given if ICP &gt; 25mmHg, and subsequent boluses were given incrementally. Eighty participants were randomised. Data were available for 40 participants in the first group, and 37 participants in the ICP-directed treatment group. Follow-up was one year.</P>
<P>
<LINK REF="STD-Vialet-2003" TYPE="STUDY">Vialet 2003</LINK> compared mannitol to hypertonic saline. Eligible patients were those with severe head injury (GCS &lt;8) who required intravenous infusions of an osmotic agent to treat episodes of intracranial hypertension resistant to standard therapy (cerebrospinal fluid drainage, volume expansion and/or inotropic support, hyperventilation). The mannitol group received 20% mannitol solution. The hypertonic saline group received 7.5% hypertonic saline. The infused volume was the same for both solutions: 2 ml/kg body weight in 20 minutes. The aim was to decrease ICP to &lt;25 mm Hg or to increase CPP to &gt;70 mm Hg. In case the first infusion failed, the patient received a second infusion within ten minutes after the end of the first infusion. Treatment failure was defined as the inability to decrease ICP to &lt;35 mm Hg or to increase CPP to &gt;70 mm Hg with two consecutive infusions of the selected osmotic solution. In that case, the protocol was stopped, and patients were followed up for mortality or 90-day neurologic status. Because 20% mannitol can crystallize at ambient temperature, injections could not be performed in a blinded manner. Twenty patients were randomised, ten to each group. Outcome was assessed at 90 days using the Glasgow Outcome Scale administered by a practitioner who was blind to acute patient care.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-05-28 17:35:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Sayre-1996" TYPE="STUDY">Sayre 1996</LINK>: The study was randomised and double-blind. Allocation concealment was by pharmacy-prepared blinded solutions.</P>
<P>
<LINK REF="STD-Schwartz-1984" TYPE="STUDY">Schwartz 1984</LINK>: The study was randomised and single-blind. Allocation concealment was by using serially numbered sealed envelopes.</P>
<P>
<LINK REF="STD-Smith-1986" TYPE="STUDY">Smith 1986</LINK>:The study was randomised but not reported as double-blind. Allocation concealment was by the use of sealed envelopes.</P>
<P>
<LINK REF="STD-Vialet-2003" TYPE="STUDY">Vialet 2003</LINK>: The study was randomised but allocation concealment was not described. Outcome assessment was blind to acute clinical care.</P>
<P>The risk of bias across the four studies is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>One trial compared ICP-directed therapy to 'standard care' in which mannitol therapy was directed by neurological signs (<LINK REF="STD-Smith-1986" TYPE="STUDY">Smith 1986</LINK>). The study was randomised and allocation concealment was by the use of sealed envelopes. For ICP-directed treatment compared to treatment based on neurological signs, the RR for death was 0.83 (95% CI 0.47 to 1.46); this trial demonstrated a similar effect for death or severe disability (RR = 0.88; 95% CI 0.55 to 1.38). </P>
<P>One trial compared mannitol to pentobarbital (<LINK REF="STD-Schwartz-1984" TYPE="STUDY">Schwartz 1984</LINK>). This trial was randomised and single blind. Only patients with known raised ICP were included. For mannitol compared to pentobarbital in the treatment of patients with raised ICP, the RR for death was 0.85 (95% CI 0.52 to 1.38).</P>
<P>One trial compared mannitol to hypertonic saline (<LINK REF="STD-Vialet-2003" TYPE="STUDY">Vialet 2003</LINK>). This trial was randomised and single blind. Only patients with head injury and persistent coma who required osmotherapy to treat episodes of intracranial hypertension resistant to standard therapy were included. For mannitol compared to hypertonic saline in the treatment of refractory intracranial hypertension episodes in comatose patients with severe head injury, the RR for death was 1.25 (95% CI 0.47 to 3.33).</P>
<P>The effectiveness of pre-hospital administration of mannitol against placebo was investigated in <LINK REF="STD-Sayre-1996" TYPE="STUDY">Sayre 1996</LINK>. This study was randomised and allocation concealment was through pharmacy prepared blinded solutions. For pre-hospital infusion of mannitol compared to placebo in patients with head injury and multiple trauma, the RR for death was 1.75 (95% CI 0.48 to 6.38).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>There were few eligible trials of mannitol therapy in head-injured patients.</P>
<P>ICP-directed treatment showed a small beneficial effect on mortality when compared to treatment directed according to neurological signs and physiological indicators (RR = 0.83; 95% CI 0.47 to 1.46). The method of allocation concealment in this study was adequate to prevent foreknowledge of treatment, and was unlikely to have led to bias. Owing to small patient numbers, the effect measure is imprecise. It must be noted that in this study the ICP-directed protocol initiated mannitol only when the ICP rose to above 25mmHg. Therefore these results cannot be extrapolated to ICP-directed protocols which initiate mannitol therapy at a lower level. </P>
<P>Mannitol therapy may have a beneficial effect on mortality when compared to pentobarbital therapy. However, the single trial which tested this (<LINK REF="STD-Schwartz-1984" TYPE="STUDY">Schwartz 1984</LINK>) yielded an imprecise effect measure, which also may be compatible with no difference, or a beneficial effect of pentobarbital. The trial was testing an initial treatment of mannitol compared to pentobarbital as some patients later received the alternate therapy if the allocated therapy failed to control ICP.</P>
<P>Mannitol therapy may have a detrimental effect on mortality when compared to hypertonic saline therapy. The single trial which compared mannitol to hypertonic saline (<LINK REF="STD-Vialet-2003" TYPE="STUDY">Vialet 2003</LINK>) was too small for reliable conclusions. The trial was not designed to test the effect of these osmotic agents on neurologic recovery or death.<BR/> <BR/>The single trial which compared pre-hospital administration of mannitol to placebo showed an increase in mortality amongst the mannitol-treated patients (RR = 1.75; 95% CI 0.48 to 6.38). The estimate yielded by this trial is imprecise owing to the small sample size. The effect measure also may be compatible with no difference, or a beneficial effect of pre-hospital administration of mannitol.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is insufficient reliable evidence to make recommendations on the use of mannitol in the management of patients with traumatic brain injury. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There are many unanswered questions regarding the optimal use of mannitol following acute traumatic head injury. The widespread current use of mannitol, and lack of clarity regarding optimal administration, present an ideal opportunity for the conduct of randomised controlled trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-11 10:17:13 +0100" MODIFIED_BY="[Empty name]">
<P>AW ran the searches, screened the citations for eligibility, extracted data, entered data into RevMan and wrote the updated review.</P>
<P>AM screened the citations for eligibility, entered data into RevMan and helped write the updated review.</P>
<P>IR screened citations, extracted data, helped to write the original review.</P>
<P>GS designed and ran the searches, screened the citations for eligibility, contacted authors, extracted data, entered data into RevMan and wrote up the original review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-05-28 16:20:33 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-05-28 16:20:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-05-28 16:20:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Sayre-1996" NAME="Sayre 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Sayre MR, Daily SW, Stern SA, Storer DL, van Loveren HR, Hurst JD. Out-ot-hostial administration of mannitol does not change systolic blood pressure. Academic Emergency Medicine 1996;3(9):840-848.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sayre MR, Daily SW, Stern SA, Storer DL, van Loveren HR, Hurst JD</AU>
<TI>Out-of-hospital administration of mannitol does not change systolic blood pressure</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>9</NO>
<PG>840-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997024527"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1984" NAME="Schwartz 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Schwartz ML, Tator CH, Rowed DW, Reid SR, Meguro K, Andrews DF. The University of Toronto head injury treatment study: a prospective, randomized comparison of pentobarbital and mannitol. Can-J-Neurol-Sci 1984; 11(4):434-40.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz ML, Tator CH, Rowed DW, Reid SR, Meguro K, Andrews DF</AU>
<TI>The University of Toronto head injury treatment study: a prospective, randomized comparison of pentobarbital and mannitol</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>4</NO>
<PG>434-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1985098889"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1986" MODIFIED="2013-05-28 16:20:33 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1986" YEAR="">
<REFERENCE MODIFIED="2013-05-28 16:20:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Smith HP, Kelly DL Jr, McWhorter JM et al. Comparison of mannitol regimens in patients with severe head injury undergoing intracranial monitoring. J-Neurosurg 1986;65(6):820-4.&lt;/p&gt;" NOTES_MODIFIED="2013-05-28 16:20:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith HP, Kelly DL Jr, McWhorter JM, Armstrong D, Johnson R, Transou C et al</AU>
<TI>Comparison of mannitol regimens in patients with severe head injury undergoing intracranial monitoring</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1986</YR>
<VL>65</VL>
<NO>6</NO>
<PG>820-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1987035848"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vialet-2003" NAME="Vialet 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vialet R, Albanese J, Thomachot L, Antonini F, Bourgouin A, Alliez B et al</AU>
<TI>Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1683-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12794404"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-12 15:33:38 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Battison-2005" NAME="Battison 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battison C, Andrews PJ, Graham C, Petty T</AU>
<TI>Randomized, controlled trial of the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury</TI>
<SO>Critical Care Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>1</NO>
<PG>196-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15644669"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-2001" NAME="Cruz 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz C, Minoja G, Okuchi K</AU>
<TI>Improving clinical outcomes from acute subdural hematomas with emergency preoperative administration of high doses of mannitol: a randomized trial</TI>
<SO>Neurosurgery</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>864-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-2002" NAME="Cruz 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz C, Minoja G, Okuchi K</AU>
<TI>Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupilary widening</TI>
<SO>Neurosurgery</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>3</NO>
<PG>628-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cruz-2004" NAME="Cruz 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cruz J, Minoja G, Okuchi K, Facco E</AU>
<TI>Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scores of 3 and bilateral abnormal pupillary widening: a randomized trial</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2004</YR>
<VL>100</VL>
<NO>3</NO>
<PG>376-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15035271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fortune-1995" NAME="Fortune 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Fortune JB; Feustel PJ; Graca I; Hasselbarth J; Kuehler DH. Effect of hyperventilation, mannitol, and ventriculostomy drainage on cerebral blood-flow after head-injury. Journal of Trauma-Injury Infection and Critical Care 1995; 39 (6):1091-1099.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fortune JB, Feustel PJ, Graca I, Hasselbarth J, Kuehler DH</AU>
<TI>Effect of hyperventilation, mannitol, and ventriculostomy drainage on cerebral blood-flow after head-injury</TI>
<SO>Journal of Trauma-Injury Infection and Critical Care</SO>
<YR>1995</YR>
<VL>39</VL>
<NO>6</NO>
<PG>1091-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francony-2008" MODIFIED="2010-05-12 15:33:38 +0100" MODIFIED_BY="[Empty name]" NAME="Francony 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-12 15:33:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francony G, Fauvage B, Falcon D, Canet C, Dilou H, Lavagne P, et al</AU>
<TI>Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure</TI>
<SO>Critical Care Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>3</NO>
<PG>795-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaab-1989" NAME="Gaab 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Gaab MR, Seegers K, Goetz C. THAM (Tromethamine, &amp;quot;Tris-Buffer&amp;quot;): Effective therapy of traumatic brain swelling? Intracranial Pressure VII Eds: JT Hoff, Betz AL. Springer-Verlag Berlin Heidelberg 1989: 616-19.&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Gaab MR, Seegers K, Goetz C</AU>
<TI>THAM (Tromethamine, "Tris-Buffer"): Effective therapy of traumatic brain swelling?</TI>
<SO>Intracranial Pressure VII</SO>
<YR>1989</YR>
<PG>616-9</PG>
<ED>Hoff JT, Betz AL</ED>
<PB>Springer-Verlag</PB>
<CY>Berlin Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harutjunyan-2005" MODIFIED="2010-05-11 12:16:03 +0100" MODIFIED_BY="[Empty name]" NAME="Harutjunyan 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-05-11 12:16:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harutjunyan L, Holz C, Rieger A, Menzel M, Grond S, Soukup J</AU>
<TI>Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial</TI>
<SO>Critical Care</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>R530-R540</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ichai-2009" MODIFIED="2010-05-11 12:19:40 +0100" MODIFIED_BY="[Empty name]" NAME="Ichai 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-11 12:19:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ichai C, Armando G, Orban J-C, Berthier F, Rami L, Samat-Long C, et al</AU>
<TI>Sodium lactate versus mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>2009</YR>
<VL>35</VL>
<PG>471-479</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-1979" NAME="Levin 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin AB, Duff TA, Javid MJ</AU>
<TI>Treatment of increased intracranial pressure: a comparison of different hyperosmotic agents and the use of thiopental</TI>
<SO>Neurosurgery</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>5</NO>
<PG>570-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Midgely-1993" NAME="Midgely 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Midgley S. CPP and SJO2 with ICP Reduction Therapy After Severe Head Injury. Intracranial Pressure 1993; 8:558-63. Springer-Verlag. New York.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Midgley S</AU>
<TI>CPP and SJO2 with ICP Reduction Therapy After Severe Head Injury</TI>
<SO>Intracranial Pressure</SO>
<YR>1993</YR>
<PG>558-63</PG>
<PB>Springer-Verlag</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smedema-1993" NAME="Smedema 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Smedema R.J. A Comparison Study Between Mannitol and Glycerol Therapy in Reducing Intracranial Pressure. Intracranial Pressure 1993; 8, 605-08. Springer-Verlag. New York. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Smedema RJA</AU>
<TI>Comparison Study Between Mannitol and Glycerol Therapy in Reducing Intracranial Pressure</TI>
<SO>Intracranial Pressure</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>605-8</PG>
<PB>Springer-Verlag</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-05-12 15:33:38 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-05-11 12:22:17 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-08 14:59:48 +0100" MODIFIED_BY="Emma M Sydenham">
<REFERENCE ID="REF-Ghajar-1995" MODIFIED="2008-08-08 14:59:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Ghajar 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ghajar J, Hariri RJ, Narayan RK et al</AU>
<TI>Survey of critical care management of comatose, head-injured patients in the United States</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>3</NO>
<PG>560-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeevaratnam-1996" MODIFIED="2008-08-08 14:59:45 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Jeevaratnam 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jeevaratnam DR, Menon DK</AU>
<TI>Survey of intensive care of severely head injured patients in the United Kingdom</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>312</VL>
<PG>994-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matta-1996" MODIFIED="2008-08-08 14:59:42 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Matta 1996" TYPE="JOURNAL_ARTICLE">
<AU>Matta B, Menon D</AU>
<TI>Severe head injury in the United Kingdom and Ireland: a survey of practice and implications for management</TI>
<SO>Critical Care Medicine</SO>
<YR>1996; 24</YR>
<VL>10</VL>
<PG>1743-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Task-Force-1995" MODIFIED="2008-08-08 14:59:39 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Task Force 1995" TYPE="BOOK">
<AU>Task force of the American Association of Neurological Surgeons and Joint Section in Neurotrauma and Critical Care</AU>
<SO>Guidelines for the management of severe head injury</SO>
<YR>1995</YR>
<PB>Brain Trauma Foundation</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-05-11 12:22:17 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-05 17:29:02 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-05 17:29:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Sayre-1996">
<CHAR_METHODS>
<P>Randomised and double blind placebo controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Moderate and severe head injury (CGS 11 and less), above 18 years of age.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Mannitol received 5ml/kg of 20% mannitol through large-bore intravenous catheter over five minutes; placebo group were given5ml/kg of 0.9% saline solution.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death was reported. Length of follow-up was two hours after hospital admission.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Testing pre-hospital administration of mannitol.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Schwartz-1984">
<CHAR_METHODS>
<P>Randomised single blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Severe head injury (GCS&lt;8). Participants had to have already been resuscitated and had raised ICP for more than 15 minutes.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The mannitol group received 20% mannitol solution at an initial dose of 1g per kg. Additional increments were given to maintain the intracranial pressure at less than 20 torr, within a serum osmolarity of mannitol of 320mOs/L. </P>
<P>The pentobarbital group received pentobarbital as an IV bolus of up to 10mg/kg, followed by a continuous infusion at 0.5-3 mg/kg/hr, provided that CPP remained above 50 torr, Additional increments of pentobarbital were given to maintain the intracranial pressure at less than 20 torr. <BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death reported. Follow-up to three months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>For subsequent episodes of raised ICP, cross-over between the groups was allowed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-1986">
<CHAR_METHODS>
<P>Randomised controlled trial; not reported as double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Severe head injury (GCS 8 or less).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Compared two regimens of guiding the administration of mannitol, one according to neurological signs and physiological measurements, and the other using ICP monitoring. The protocol for the first group used neurological signs, GCS, ventilatory values and arterial blood gas to guide administration. In the second group, a 250ml bolus of mannitol (20%) was given if ICP &gt;25mmHg, and subsequent boluses were given incrementally.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Deaths and neurological disability were reported. Follow-up was one year.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vialet-2003">
<CHAR_METHODS>
<P>Randomised single blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Severe head injury (GCS&lt;8) who required intravenous infusions of an osmotic agent to treat episodes of intracranial hypertension resistant to standard therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Compared two osmotic agents, mannitol and hypertonic saline solution. The mannitol group received 20% mannitol solution. The hypertonic saline group received 7.5% hypertonic saline. The infused volume was the same for both solutions: 2 ml/kg body weight in 20 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death and neurological disability reported. Follow-up to three months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-12 15:36:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Battison-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-05 15:40:59 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Cruz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 15:40:59 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-05 15:41:02 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Cruz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 15:41:02 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-05-05 15:41:07 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Cruz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-05-05 15:41:07 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Concerns about the integrity of the trial data. Manuscripts does not indicate where the patients were randomised and despite an investigation by the Cochrane Injuries Group this remains open to question.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fortune-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Controlled follow up study; no means to reduce bias in the selection of the control group was used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-12 15:36:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Francony-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-12 15:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were not all head-injured patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gaab-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised to a diuretic, not necessarily mannitol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-11 12:17:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harutjunyan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-11 12:17:27 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were not all head-injured patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-11 12:20:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ichai-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-11 12:20:38 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levin-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were not all head injured; had a cross-over design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Midgely-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over design.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-11 12:17:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smedema-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-11 12:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were not all head-injured patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-05-12 15:33:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-08-05 17:29:02 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-08-05 17:03:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 07:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sayre-1996">
<DESCRIPTION>
<P>Information not provided in published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 17:03:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schwartz-1984">
<DESCRIPTION>
<P>Quote: "The starting drug was determined by a random number generator."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 15:42:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1986">
<DESCRIPTION>
<P>No information provided in published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 16:17:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vialet-2003">
<DESCRIPTION>
<P>No information provided in published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-05 17:06:30 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-12 07:10:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sayre-1996">
<DESCRIPTION>
<P>Quote: "The study solutions were prepared by the pharmacy department and were identified by a code number. An envelope showing the code number identified the contents of that IV bag. If the treating physicians at the receiving trauma center believed it was necessary to know whether the patient had received mannitol or placebo, the envelope could be opened".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-05 17:06:30 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="YES" STUDY_ID="STD-Schwartz-1984">
<DESCRIPTION>
<P>Quote: "The mechanism of randomization was the opening of a serially-numbered, sealed envelope taken from one of two packages of envelopes, one for patients who had had intracranial hematomas removed and one for those who developed raised intracranial pressure from brain injury alone."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 16:02:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1986">
<DESCRIPTION>
<P>Quote: "The patients were randomly assigned to one of two groups by means of sealed envelopes containing cards designating the assigned protocol: Group I (mannitol therapy based on ICP monitoring) or Group II (empirical mannitol therapy)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 16:22:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Vialet-2003">
<DESCRIPTION>
<P>Quote: "After randomization, the patients received either 20% mannitol (1160 mOsm/kg/H2O) or 7.5% HSS (2400 mOsm/kg/H2O)".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-08-05 17:29:02 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-28 16:18:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sayre-1996">
<DESCRIPTION>
<P>Comment: Blinding is implied but not explicitly stated.</P>
<P>Quote: "This was a prospective, randomized, double-blind, placebo-controlled clinical trial of the effect of mannitol on systolic BP in multiply injured patients with severe head injuries".</P>
<P>Quote: "The study solutions were prepared by the pharmacy department and were identified by a code number. An envelope showing the code number identified the contents of that IV bag. If the treating physicians at the receiving trauma center believed it was necessary to know whether the patient had received mannitol or placebo, the envelope could be opened".</P>
<P>Quote: "At the conclusion of the 2-hour monitoring period, the EM resident and the investigator recording the patient data were asked to provide their guesses as to whether mannitol or placebo had been administered to the patient. For those patients actually given mannitol, the resident correctly picked mannitol in 11 of 13 cases for which a guess was given; and the investigators correctly picked mannitol in 13 of 14 cases. For those patients actually given placebo, the resident correctly picked placebo in 5 of 10 cases for which a guess was given; and the investigators correctly picked placebo for 13 of 16 cases".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-28 17:34:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schwartz-1984">
<DESCRIPTION>
<P>.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-05-28 16:18:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1986">
<DESCRIPTION>
<P>No information provided in published study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-05 17:29:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vialet-2003">
<DESCRIPTION>
<P>Quote: "Because 20% mannitol can crystallize at ambient temperature, injections could not be performed in a blinded manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-05-29 11:08:41 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-05-29 11:07:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ICP-directed mannitol ('treatment') compared to mannitol according to neurological signs ('control')</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-29 11:07:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4576129287563697" CI_START="0.4688815938133126" EFFECT_SIZE="0.8267090620031796" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.16364221175752325" LOG_CI_START="-0.32893681537846275" LOG_EFFECT_SIZE="-0.08264730181046978" ORDER="12193" O_E="0.0" SE="0.28934335884518697" STUDY_ID="STD-Smith-1986" TOTAL_1="37" TOTAL_2="40" VAR="0.08371957930781462" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-29 11:07:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="37" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death or severe disability</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.382448229922175" CI_START="0.554021872815784" EFFECT_SIZE="0.8751608751608752" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.1406488767723211" LOG_CI_START="-0.25647308896167703" LOG_EFFECT_SIZE="-0.05791210609467795" ORDER="12194" O_E="0.0" SE="0.23327140845758465" STUDY_ID="STD-Smith-1986" TOTAL_1="37" TOTAL_2="40" VAR="0.05441555000378529" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-05-29 11:08:08 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Mannitol versus pentobarbital</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-29 11:08:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="28" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3750974224884738" CI_START="0.5214368983122223" EFFECT_SIZE="0.8467741935483871" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.13833346802107216" LOG_CI_START="-0.2827982402056662" LOG_EFFECT_SIZE="-0.07223238609229699" ORDER="12195" O_E="0.0" SE="0.24737485004796245" STUDY_ID="STD-Schwartz-1984" TOTAL_1="31" TOTAL_2="28" VAR="0.06119431643625191" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-05-29 11:08:24 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Mannitol versus hypertonic saline</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-29 11:08:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="12196" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Vialet-2003" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-05-29 11:08:41 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Mannitol versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-05-29 11:08:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.381235307339195" CI_START="0.47992275045519056" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8049047594781772" LOG_CI_START="-0.3188286621055883" LOG_EFFECT_SIZE="0.24303804868629444" ORDER="12197" O_E="0.0" SE="0.6600865744084526" STUDY_ID="STD-Sayre-1996" TOTAL_1="20" TOTAL_2="21" VAR="0.4357142857142857" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-08-05 17:29:03 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-05 17:29:03 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAMMAAAGSCAIAAADRuOIbAAANjElEQVR42u2dvW4USRDHV0I6EThw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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-08-05 17:29:03 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. Four studies are included in this review.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAACcCAMAAACa91sKAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Mannitol for acute traumatic brain injury</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>A. The search strategy would be clearer if the reviewer specified what additional search terms were used within the Injuries Group database to identify relevant articles (e.g., mannitol And acute brain injury). Also, the report does not specify whether any other databases, such as Medline or Embase, were searched, and if so, what search terms were used. The search should specify the total number of reports that were identified by the search strategy.</P>
<P>B. Would it be correct to interpret the review as demonstrating that there is no good evidence (i.e. no RCT's comparing mannitol to placebo or alternate therapies) to support our current mannitol use post-head injury? Presumably current use of mannitol by clinicians is based primarily on the pharmacological activities of mannitol, observational human studies, and animal evidence supporting its potential benefit.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>A. We did not use any additional search terms in the Injuries Group database apart from 'mannitol'. No other databases, such as EMBASE, were searched separately (these searches were already included in the Injuries Group database).</P>
<P>B. Yes - the review concludes that there is a lack of evidence for effectiveness, which is not the same as saying there is evidence of a lack of effectiveness.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Dr Michael Bullard</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-05-28 16:09:29 +0100" MODIFIED_BY="Emma M Sydenham">
<APPENDIX ID="APP-01" MODIFIED="2013-05-28 16:09:29 +0100" MODIFIED_BY="Emma M Sydenham" NO="1">
<TITLE MODIFIED="2013-05-28 16:09:29 +0100" MODIFIED_BY="Emma M Sydenham">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-28 16:09:17 +0100" MODIFIED_BY="Emma M Sydenham">
<P>
<B>Cochrane Injuries Group&#8217;s Specialised Register</B>
<BR/>(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol or nsc-94* or osmitrol or osmofundin or "(l)-mannitol" or "Dextro Mannitol" or D-Mannitol or (diuretic* and osmotic*)) AND (&#8220;intracranial pressure&#8221; OR &#8220;intracranial hypotension&#8221; OR &#8220;intracranial hypertension&#8221; or head* or brain*)<BR/>
<B>
<BR/>CENTRAL (The Cochrane Library)</B>
<BR/>#1MeSH descriptor Craniocerebral Trauma explode all trees<BR/>#2MeSH descriptor Cerebrovascular Trauma explode all trees<BR/>#3MeSH descriptor Brain Edema explode all trees<BR/>#4(brain or cerebral or intracranial) next (oedema or edema or swell*)<BR/>#5MeSH descriptor Glasgow Coma Scale explode all trees<BR/>#6MeSH descriptor Glasgow Outcome Scale explode all trees<BR/>#7MeSH descriptor Unconsciousness explode all trees<BR/>#8glasgow next (coma or outcome) next (score or scale)<BR/>#9(Unconscious* or coma* or concuss* or 'persistent vegetative state') near5 (injur* or trauma* or damag* or wound* or fracture*)<BR/>#10"Rancho Los Amigos Scale"<BR/>#11(head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) near3 (injur* or trauma* or damag* or wound* or fracture* or contusion*)<BR/>#12Diffuse next axonal next injur*<BR/>#13(head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) near3 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)<BR/>#14(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)<BR/>#15MeSH descriptor Mannitol explode all trees<BR/>#16MeSH descriptor Diuretics, Osmotic explode all trees<BR/>#17(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol or nsc-94* or osmitrol or osmofundin or "(l)-mannitol" or Dextro Mannitol or D-Mannitol or (diuretic* adj5 osmotic*)).ab,ti.<BR/>#18(#15 OR #16 OR #17)<BR/>#19 (#14 and #18)<BR/>
<BR/>
<BR/>
<B>MEDLINE (OvidSP)</B>
<BR/>1.exp mannitol/<BR/>2.exp Diuretics, Osmotic/<BR/>3.(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol or nsc-94* or osmitrol or osmofundin or "(l)-mannitol" or Dextro Mannitol or D-Mannitol or (diuretic* adj5 osmotic*)).ab,ti.<BR/>4.1 or 2 or 3<BR/>5.exp Craniocerebral Trauma/<BR/>6.exp Brain Edema/<BR/>7.exp Glasgow Coma Scale/<BR/>8.exp Glasgow Outcome Scale/<BR/>9.exp Unconsciousness/<BR/>10.exp Cerebrovascular Trauma/<BR/>11.((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj5 (injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.<BR/>12.((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj5 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)).ti,ab.<BR/>13.(Glasgow adj (coma or outcome) adj (scale* or score*)).ab,ti.<BR/>14."rancho los amigos scale".ti,ab.<BR/>15.("diffuse axonal injury" or "diffuse axonal injuries").ti,ab.<BR/>16.((brain or cerebral or intracranial) adj3 (oedema or edema or swell*)).ab,ti.<BR/>17.((unconscious* or coma* or concuss* or 'persistent vegetative state') adj3 (injur* or trauma* or damag* or wound* or fracture*)).ti,ab.<BR/>18.exp coma/<BR/>19.or/5-18<BR/>20.4 and 19<BR/>21.randomi?ed.ab,ti.<BR/>22.randomized controlled trial.pt.<BR/>23.controlled clinical trial.pt.<BR/>24.placebo.ab.<BR/>25.clinical trials as topic.sh.<BR/>26.randomly.ab.<BR/>27.trial.ti.<BR/>28.21 or 22 or 23 or 24 or 25 or 26 or 27<BR/>29.(animals not (humans and animals)).sh.<BR/>30.28 not 29<BR/>31.30 and 20<BR/>
<BR/>EMBASE (OvidSP)<BR/>1.exp mannitol/<BR/>2.exp Osmotic Diuretic Agent/<BR/>3.(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol or nsc-94* or osmitrol or osmofundin or "(l)-mannitol" or Dextro Mannitol or D-Mannitol or (diuretic* adj5 osmotic*)).ab,ti.<BR/>4.1 or 2 or 3<BR/>5.exp Brain Injury/<BR/>6.exp Brain Edema/<BR/>7.exp Glasgow Coma Scale/<BR/>8.exp Glasgow Outcome Scale/<BR/>9.exp Rancho Los Amigos Scale/<BR/>10.exp Unconsciousness/<BR/>11.((brain or cerebral or intracranial) adj5 (oedema or edema or swell*)).ab,ti.<BR/>12.((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj5 (injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti.<BR/>13.(Glasgow adj (coma or outcome) adj (scale* or score*)).ab,ti.<BR/>14.Rancho Los Amigos Scale.ab,ti.<BR/>15.((unconscious* or coma* or concuss* or 'persistent vegetative state') adj3 (injur* or trauma* or damag* or wound* or fracture*)).ti,ab.<BR/>16.Diffuse axonal injur*.ab,ti.<BR/>17.((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)).ab,ti.<BR/>18.or/5-17<BR/>19.exp Randomized Controlled Trial/<BR/>20.exp controlled clinical trial/<BR/>21.randomi?ed.ab,ti.<BR/>22.placebo.ab.<BR/>23.*Clinical Trial/<BR/>24.randomly.ab.<BR/>25.trial.ti.<BR/>26.19 or 20 or 21 or 22 or 23 or 24 or 25<BR/>27.exp animal/ not (exp human/ and exp animal/)<BR/>28.26 not 27<BR/>29.28 and 18<BR/>30.4 and 29<BR/>
<BR/>
<B>ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) &amp; Conference Proceedings Citation Index- Science (CPCI-S)</B>
<BR/>1.Topic=(mannitol or Mannit or Mannite or Osmosal or Osmosteril or Resectisol or Aridol or Bronchitol or bromine or mitobronitol or dibromomannitol or myelobromol) OR Topic=(nsc-94* or osmitrol or osmofundin or "(l)-mannitol" or "Dextro Mannitol" or D-Mannitol or (diuretic* and osmotic*))<BR/>2.Topic=(intracranial pressure OR intracranial hypotension OR intracranial hypertension or head* or brain*)<BR/>3.TS=(clinical OR control* OR placebo OR random OR randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly allocated OR at random) SAME TS=(trial* or group* or study or studies or placebo or controlled)<BR/>4.1 and 2 and 3<BR/>
<BR/>
<B>PubMed</B>
<BR/>1.(Mannitol OR Mannit OR Mannite OR Osmosal OR Osmosteril OR Resectisol OR Aridol OR Bronchitol OR Bromine OR Mitobronitol OR Dibromomannitol OR Myelobromol OR Nsc-94* OR Osmitrol OR Osmofundin OR "(l)-mannitol" OR "Dextro Mannitol" OR D-Mannitol OR (diuretic* and osmotic*))<BR/>2.(&#8220;intracranial pressure&#8221; OR &#8220;intracranial hypotension&#8221; OR &#8220;intracranial hypertension&#8221; OR head OR brain)<BR/>3.((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab]) OR (trial[ti]) OR ("Clinical Trials as Topic"[MeSH Major Topic])) NOT (("Animals"[Mesh]) NOT ("Humans"[Mesh] AND "Animals"[Mesh]))<BR/>4.#1 AND #2 AND #3<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>